Eradication of HIV infection cannot be achieved with available antiretroviral (ARV) regimens even when new, potent drugs are added to a regimen that is already suppressing plasma viral load below the limits of detection of commercially available assays.1This is chiefly because the pool of latently infected CD4 T cells is established during the earliest stages of acute HIV infection2and persists with a long half-life, despite prolonged suppression of plasma viremia.3-7Therefore the primary goals for initiating antiretroviral therapy (ART) are to: